Biomarkers and Prognostic Staging*

Transthyretin Amyloid Cardiomyopathy   >   Additional Information   >   Biomarkers and Prognostic Staging   >   Introduction

For classifying into prognostic stages, cardiac biomarkers in combination with other hematologic markers have been used in the clinical management of Light-Chain cardiac amyloidosis. As the field of amyloidosis continues to develop, the experience in Light-Chain amyloidosis has been extrapolated into ATTR-CM (Transthyretin Amyloid Cardiomyopathy)1

Prognostic Staging Models Based on Biomarkers and eGFR
Model Risk Factor
cTnT
(ng/ml)		 NT-proBNP
(pg/ml)		 eGFR
(ml/min/1.73m2)
Mayo (ATTRwt)2 >0.05 >3,000
National Amyloidosis Center
([NAC] ATTRwt and ATTRv)3		 >3,000 <45
 
Prognostic Stages Description
1 Absence of any risk factor
2 Presence of 1 risk factor
3 Presence of 2 risk factors
*The staging systems data are pre-dated to a treatment becoming U.S. FDA approved for ATTR-CM in the year 2019